-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Viridian Therapeutics, Raises Price Target to $39

Benzinga·08/07/2026 13:27:11
Listen to the news
Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $38 to $39.